Implications for Practice
CINV
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
This was a phase III randomized clinical trial for control of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy using olanzapine with or without an NK-1. A previous study demonstrated that adding olanzapine to an NK-1, 5 HT3, and dexamethasone improved control of CINV. The current study considered whether an NK-1 is needed to control CINV if olanzapine is used. This is an important question when deciding the antiemetic regimens prior to chemotherapy.